



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/719221/2014

European Medicines Agency decision

P/0319/2014

of 19 December 2014

on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMA-000454-PIP01-08-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0319/2014

of 19 December 2014

on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMA-000454-PIP01-08-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/187/2009 issued on 8 September 2009, the decision P/73/2010 issued on 5 May 2010, the decision P/0275/2012 issued on 21 November 2012, the decision P/0290/2013 issued on 29 November 2013, and the decision P/0085/2014 issued on 4 April 2014,

Having regard to the application submitted by Kedrion S.p.A. on 26 August 2014 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 November 2014, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for human normal immunoglobulin, solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Kedrion S.p.A., Loc. Ai Conti, 55051 - Castelvecchio Pascoli - Barga (Lucca), Italy.

Done at London, 19 December 2014

For the European Medicines Agency
Zaide Frias
Head of Division (ad interim)
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/529182/2014 **Corr**

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-000454-PIP01-08-M05

Scope of the application

Active substance(s):

Human normal immunoglobulin

Condition(s):

Treatment of Primary Immunodeficiency (PID)

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name / corporate name of the PIP applicant:

Kedrion S.p.A.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Kedrion S.p.A. submitted to the European Medicines Agency on 26 August 2014 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/187/2009 issued on 8 September 2009, the decision P/73/2010 issued on 5 May 2010, the decision P/0275/2012 issued on 21 November 2012, the decision P/0290/2013 issued on 29 November 2013, and the decision P/0085/2014 issued on 4 April 2014.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 16 September 2014.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 14 November 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition: treatment of primary immunodeficiency (PID)

Primary immunodeficiency (PID) as model for replacement therapy

This covers replacement therapy in:

- Primary immunodeficiency syndromes;
- Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinemia and recurrent infections;
- Children with congenital AIDS and recurrent infections.

The waiver applies to:

- all subsets of the paediatric population from birth to less than 24 months of age;
- for the solution for infusion for subcutaneous use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit.

2. Paediatric Investigation Plan

2.1. Condition: treatment of primary immunodeficiency (PID)

2.1.1. Indication(s) targeted by the PIP

Replacement therapy in primary immunodeficiency syndrome (PID) as a model for replacement therapy in primary immunodeficiency syndrome (PID), in myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinemia and recurrent infections and in children with congenital AIDS and recurrent infections

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 24 months to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Human normal immunoglobulin Solution for injection for subcutaneous use 160 g/L.

2.1.4. Measures

Area	Number of measures	Description
Quality related studies		Not applicable.
Non-clinical studies		Not applicable.

Area	Number of measures	Description
Clinical studies	1	Study 1: KB 047 bis Open-label, multicenter study to evaluate the efficacy and safety of subcutaneous immunoglobulin preparation in the treatment of primary immunodeficiency patients from 2 to less than 18 years of age.
Extrapolation, modelling and simulation studies		Not applicable.
Other studies		Not applicable.
Other measures		Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2016
Deferral for one or more studies contained in the paediatric investigation plan:	Yes